Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis).
Novel MRI metric predicts late genitourinary toxicity after prostate cancer treatment
A new Corewell Health study suggests that men who have longer prostatic urethras, the part of the urethra that travels through the prostate, may be
October 18, 2023